Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
82 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Spectrum Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Spectrum Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Spectrum Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Spectrum Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Spectrum Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Spectrum Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Spectrum Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Spectrum Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Spectrum Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Spectrum Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Spectrum Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Spectrum Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Spectrum Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Spectrum Pharmaceuticals, Inc. Snapshot 6 Spectrum Pharmaceuticals, Inc. Overview 6 Key Information 6 Key Facts 6 Spectrum Pharmaceuticals, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Spectrum Pharmaceuticals, Inc. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Spectrum Pharmaceuticals, Inc. - Pipeline Products Glance 14 Spectrum Pharmaceuticals, Inc. - Late Stage Pipeline Products 14 Pre-Registration Products/Combination Treatment Modalities 14 Phase III Products/Combination Treatment Modalities 15 Spectrum Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Spectrum Pharmaceuticals, Inc. - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Spectrum Pharmaceuticals, Inc. - Drug Profiles 19 belinostat 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 apaziquone 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ibritumomab tiuxetan 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 pralatrexate 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 vincristine sulfate liposomal 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 lucanthone hydrochloride 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 melphalan 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 menadione 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ortataxel 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ozarelix 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 SPI-014 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 SPI-1620 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 leteprinim potassium lipid suspension 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 MTRN-2696 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 topotecan hydrochloride liposomal 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 vinorelbine tartrate liposomal 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 rituximab biosimilar 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Spectrum Pharmaceuticals, Inc. - Pipeline Analysis 51 Spectrum Pharmaceuticals, Inc. - Pipeline Products by Target 51 Spectrum Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 53 Spectrum Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 54 Spectrum Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 55 Spectrum Pharmaceuticals, Inc. - Recent Pipeline Updates 57 Spectrum Pharmaceuticals, Inc. - Dormant Projects 75 Spectrum Pharmaceuticals, Inc. - Discontinued Pipeline Products 77 Discontinued Pipeline Product Profiles 77 efaproxiral 77 ortataxel 77 ozarelix 77 RH-1 77 Spectrum Pharmaceuticals, Inc. - Company Statement 78 Spectrum Pharmaceuticals, Inc. - Locations And Subsidiaries 79 Head Office 79 Other Locations & Subsidiaries 79 Appendix 81 Methodology 81 Coverage 81 Secondary Research 81 Primary Research 81 Expert Panel Validation 81 Contact Us 82 Disclaimer 82
List of Tables Spectrum Pharmaceuticals, Inc., Key Information 6 Spectrum Pharmaceuticals, Inc., Key Facts 6 Spectrum Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 Spectrum Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 10 Spectrum Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 11 Spectrum Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 12 Spectrum Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 13 Spectrum Pharmaceuticals, Inc. - Pre-Registration, 2014 14 Spectrum Pharmaceuticals, Inc. - Phase III, 2014 15 Spectrum Pharmaceuticals, Inc. - Phase II, 2014 16 Spectrum Pharmaceuticals, Inc. - Phase I, 2014 17 Spectrum Pharmaceuticals, Inc. - Preclinical, 2014 18 Spectrum Pharmaceuticals, Inc. - Pipeline by Target, 2014 52 Spectrum Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 53 Spectrum Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 54 Spectrum Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 56 Spectrum Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 57 Spectrum Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 75 Spectrum Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 77 Spectrum Pharmaceuticals, Inc., Other Locations 79 Spectrum Pharmaceuticals, Inc., Subsidiaries 79
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
